Genetics - Recording a family history
Dr John Spicer and Dr Imran Rafi explain how to create a genetic map. Read more
Yesterday, Eisai, manufacturers of the Alzheimer's drug donepezil (Aricept), won its argument to be given an executable version of the economical model used by NICE when it decided the drug should not be given to patients with mild Alzheimer's disease.
NICE chief executive Andrew Dillon said: ‘The ruling will increase the complexity of our drug appraisals in some cases and they may take longer as a result.
‘In the meantime, and in accordance with the judges' ruling, we will provide Eisai with an executable version of the economical model used in our appraisal, so that it can comment on it,' he added.
‘We will then take those comments into account.'
Although a ‘read-only'version of NICE's economic model is available, the Court of Appeal ruled that an ‘executable' version including additional functions and calculations was made available to Eisai.
NICE said the economical model is put together differently for each technology appraisal. The ruling applies to this individual case and may not be borne out in other appeals.
The Association of the British Pharmaceutical Industry (ABPI) welcomed the Court of Appeal ruling.
‘This judgement provides further momentum behind the drive to make NICE processes more transparent,' said ABPI director general Dr Richard Barker.
Do you think NICE needs to be more transparent? Comment below and tell us what you think.
Quick search - use * for an abbreviated search, eg nico*
Dr John Spicer and Dr Imran Rafi explain how to create a genetic map. Read more
An apology and sympathy can go a long way to resolving a grievance, explains the MDDUS's medico-lega... Read more
Play out the doctor, patient and assessor roles in a study group or plan on your own how you would a... Read more
Contributed by Mr Antonio V Antoniou, consultant gynaecologist and lead in minimal access surgery an... Read more
Dr Mark Ritchie, GPSI in pain management, Morriston, Swansea Read more
Contributed by Dr Mark Ritchie, GPSI in pain management, Morriston, Swansea Read more
Janssen-Cilag has launched Stelara for the treatment of moderate to severe plaque psoriasis where ot... Read more
Nicorette Invisipatch is the latest addition to the range of available nicotine replacement therapy ... Read more
Flamasacard, a prolonged-release formulation of aspirin, for secondary prophylaxis after a first cor... Read more
Comments
Only registered users may comment. Log in now or register for a free account.
There are problems with your form submission.
Please review the errors shown below.